Famotidin: Razlika med redakcijama

Famotidin
Klinični podatki
Izgovarjava	/fəˈmɒtɪdiːn/
Blagovne znamke	Ulfamid, Pepcid, drugi
AHFS/Drugs.com	monograph
MedlinePlus	a687011
Licenčni podatki	ZDA FDA: Famotidine;
Nosečnostna; kategorija	AU: B1 ; ZDA: B (raziskave na živalih niso dokazale škodljivosti) ; ;
Način uporabe	peroralno (tablete), intravensko
Oznaka ATC	A02BA03 (WHO) ;
Pravni status
Pravni status	AU: Pharmacist only S3/S4 ; UK: General Availability (OTC) ; ZDA: BRp ;
Farmakokinetični podatki
Biološka razpoložljivost	40–45 % (peroralno)
Vezava na beljakovine	15–20 %
Presnova	jetrna
Razpolovni čas	2,5–3,5 h
Izločanje	skozi ledvice (25–30 % v nespremenjeni obliki po peo+roralnem vnosu)
Identifikatorji
	IUPAC ime 3-[({2-[(diaminometiliden)amino]-1,3-tiazol-4-l}metil)sulfanil]-N'-sulfamoilpropanimidamid;
Številka CAS	76824-35-6;
PubChem CID	3325;
IUPHAR/BPS	7074;
DrugBank	DB00927;
ChemSpider	3208;
UNII	5QZO15J2Z8;
KEGG	D00318;
ChEBI	CHEBI:4975;
ChEMBL	ChEMBL902;
CompTox Dashboard (EPA)	DTXSID5023039 ;
ECHA InfoCard	100.116.793
Kemični in fizikalni podatki
Formula	C8H15N7O2S3
Mol. masa	337,449 g/mol
3D model (JSmol)	Interactive image;
	SMILES NS(=O)(=O)/N=C(\N)CCSCc1csc(n1)N=C(N)N;
	InChI InChI=1S/C8H15N7O2S3/c9-6(15-20(12,16)17)1-2-18-3-5-4-19-8(13-5)14-7(10)11/h4H,1-3H2,(H2,9,15)(H2,12,16,17)(H4,10,11,13,14); Key:XUFQPHANEAPEMJ-UHFFFAOYSA-N;

Novejše urejanje →

Izbrisana vsebina Dodana vsebina

VizualnoVikibesedilo

Znotrajvrstično

Redakcija: 22:55, 11. februar 2017

Famotidín je učinkovina iz skupine zaviralcev histaminskih receptorjev H2, ki zavira izločanje želodčne kisline in se uporablja za zdravljenje peptična peptične razjede in gastroezofagealne refluksne bolezni.^[3] Na trdu je prisoten med drugim pod tržnim imenom Pepcid,^[4] v Sloveniji je registriran pod imenom Ulfamid.^[1]

Za razliko od cimetidina, najstarejšega predstavnika zaviralcev histaminskih receptorjev H2, famotidin ne izkazuje učinka na encimski sistem citokroma P450 in ne součinkuje z drugimi zdravili.^[5]

Famotidin so odkrili leta 1979.^[6]

Uporaba

Famotidin se uporablja za:

lajšanje zgage;
zdravljenje želodčnih in dvanajstnikovih razjed;
zdravljenje patoloških stanj prekomernega izločanja želodčne kisline, kot sta Zollinger–Ellisonov sindrom in multipli endokrini adenom;
zdravljenje gastroezofagealne refluksne bolezni;
zdravljenje ezofagitisa;
v kombinaciji z drugimi zdravili za eradikacijo okužbe želodčne sluznice z bakterijo Helicobacter pylori, vendar omeprazol izkazuje boljšo učinkovitost;^[7]^[8]^[9]^[10]^[11]^[12]
preprečevanje nastanka peptičnih razjed zaradi uporabe nesteroidnih protivnetnih zdravil;^[13]^[14]
pred operacijami za zmanjšanje tveganja za aspiracijsko pljučnico;^[15]^[16]^[17]

Uporablja se tudi v veterinarski medicini, pri psih in mačkih z refluksno boleznijo.^[18]

V kombinaciji z učinkovino iz skupine zaviralcev histaminskih receptorjev H1 se uporablja za zdravljenje in preprečevanje koprivnice, ki jo povzroča akutna alergijska reakcija.^[19]

Neželeni učinki

Famotidin med drugim povzroča glavobol, omotico, zaprtje in drisko.^[20]

glej tudi

Sklici

↑ ^1,0 ^1,1 http://www.cbz.si/cbz/bazazdr2.nsf/Search?SearchView&Query=(%5BSEZNAMUCINKNAZIV%5D=_famotidin*)&SearchOrder=4&SearchMax=301, Centralna baza zdravil, vpogled: 11. 2. 2017.
↑ ^2,0 ^2,1 ^2,2 ^2,3 Truven Health Analytics, Inc. DRUGDEX® System (Internet) [cited 2013 Oct 10]. Greenwood Village, CO: Thomsen Healthcare; 2013.
↑ http://www.termania.net/slovarji/slovenski-medicinski-slovar/5514909/famotidin?query=famotidin&SearchIn=All, Slovenski medicinski e-slovar, vpogled: 11. 2. 2017.
↑ http://www.webmd.com/drugs/2/drug-5035-2033/famotidine-oral/famotidine---oral/details, vpogled: 11. 2. 2017.
↑ Humphries TJ, Merritt GJ (Avgust 1999). »Review article: drug interactions with agents used to treat acid-related diseases« (pdf). Aliment. Pharmacol. Ther. 13 (Suppl 3): 18–26. doi:10.1046/j.1365-2036.1999.00021.x. PMID 10491725.
↑ Fischer, Janos (2010). Analogue-based Drug Discovery II. John Wiley & Sons. str. 4. ISBN 978-3-527-63212-1.
↑ Kanayama, S (Januar 1999). »Proton-pump inhibitors versus H2-receptor antagonists in triple therapy for Helicobacter pylori eradication«. Nihon rinsho. Japanese journal of clinical medicine. 57 (1): 153–6. PMID 10036954.
↑ Soga, T; Matsuura, M; Kodama, Y; Fujita, T; Sekimoto, I; Nishimura, K; Yoshida, S; Kutsumi, H; Fujimoto, S (Avgust 1999). »Is a proton pump inhibitor necessary for the treatment of lower-grade reflux esophagitis?«. Journal of gastroenterology. 34 (4): 435–40. doi:10.1007/s005350050292. PMID 10452673.
↑ Borody, TJ; Andrews, P; Fracchia, G; Brandl, S; Shortis, NP; Bae, H (Oktober 1995). »Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori«. Gut. 37 (4): 477–81. doi:10.1136/gut.37.4.477. PMID 7489931.
↑ Hu, FL; Jia, JC; Li, YL; Yang, GB (2003). »Comparison of H2-receptor antagonist- and proton-pump inhibitor-based triple regimens for the eradication of Helicobacter pylori in Chinese patients with gastritis or peptic ulcer«. The Journal of international medical research. 31 (6): 469–74. doi:10.1177/147323000303100601. PMID 14708410.
↑ Kirika, NV; Bodrug, NI; Butorov, IV; Butorov, SI (2004). »[Efficacy of different schemes of anti-helicobacter therapy in duodenal ulcer]«. Terapevticheskii arkhiv. 76 (2): 18–22. PMID 15106408.
↑ Fujiwara, Y; Higuchi, K; Nebiki, H; Chono, S; Uno, H; Kitada, K; Satoh, H; Nakagawa, K; Kobayashi, K; Tominaga, K; Watanabe, T; Oshitani, N; Arakawa, T (Junij 2005). »Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease«. Alimentary pharmacology & therapeutics. 21 Suppl 2: 10–8. doi:10.1111/j.1365-2036.2005.02468.x. PMID 15943841.
↑ La Corte, R; Caselli, M; Castellino, G; Bajocchi, G; Trotta, F (Junij 1999). »Prophylaxis and treatment of NSAID-induced gastroduodenal disorders«. Drug safety. 20 (6): 527–43. doi:10.2165/00002018-199920060-00006. PMID 10392669.
↑ Laine, L; Kivitz, AJ; Bello, AE; Grahn, AY; Schiff, MH; Taha, AS (Marec 2012). »Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers«. The American journal of gastroenterology. 107 (3): 379–86. doi:10.1038/ajg.2011.443. PMID 22186979.
↑ Escolano, F; Castaño, J; López, R; Bisbe, E; Alcón, A (Oktober 1992). »Effects of omeprazole, ranitidine, famotidine and placebo on gastric secretion in patients undergoing elective surgery«. British journal of anaesthesia. 69 (4): 404–6. doi:10.1093/bja/69.4.404. PMID 1419452.
↑ Vila, P; Vallès, J; Canet, J; Melero, A; Vidal, F (november 1991). »Acid aspiration prophylaxis in morbidly obese patients: famotidine vs. ranitidine«. Anaesthesia. 46 (11): 967–9. doi:10.1111/j.1365-2044.1991.tb09860.x. PMID 1750602.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
↑ Jahr, JS; Burckart, G; Smith, SS; Shapiro, J; Cook, DR (Julij 1991). »Effects of famotidine on gastric pH and residual volume in pediatric surgery«. Acta anaesthesiologica Scandinavica. 35 (5): 457–60. doi:10.1111/j.1399-6576.1991.tb03328.x. PMID 1887750.
↑ »Famotidine«.
↑ Fogg TB, Semple D (29. november 2007). »Combination therapy with H2 and H1 antihistamines in acute, non compromising allergic reactions«. BestBets. Manchester, England: Manchester Royal Infirmary. Pridobljeno 26. aprila 2011.
↑ »Pepcid Side Effects & Drug Interactions«. RxList.com. 2008. Pridobljeno 31. julija 2008.

[cbz-1] 1,0 ^1,1 http://www.cbz.si/cbz/bazazdr2.nsf/Search?SearchView&Query=(%5BSEZNAMUCINKNAZIV%5D=_famotidin*)&SearchOrder=4&SearchMax=301, Centralna baza zdravil, vpogled: 11. 2. 2017.

[DP-2] 2,0 ^2,1 ^2,2 ^2,3 Truven Health Analytics, Inc. DRUGDEX® System (Internet) [cited 2013 Oct 10]. Greenwood Village, CO: Thomsen Healthcare; 2013.

[3] ttp://www.termania.net/slovarji/slovenski-medicinski-slovar/5514909/famotidin?query=famotidin&SearchIn=All, Slovenski medicinski e-slovar, vpogled: 11. 2. 2017.

[4] ttp://www.webmd.com/drugs/2/drug-5035-2033/famotidine-oral/famotidine---oral/details, vpogled: 11. 2. 2017.

[5] Humphries TJ, Merritt GJ (Avgust 1999). »Review article: drug interactions with agents used to treat acid-related diseases« (pdf). Aliment. Pharmacol. Ther. 13 (Suppl 3): 18–26. doi:10.1046/j.1365-2036.1999.00021.x. PMID 10491725.

[6] Fischer, Janos (2010). Analogue-based Drug Discovery II. John Wiley & Sons. str. 4. ISBN 978-3-527-63212-1.

[7] Kanayama, S (Januar 1999). »Proton-pump inhibitors versus H2-receptor antagonists in triple therapy for Helicobacter pylori eradication«. Nihon rinsho. Japanese journal of clinical medicine. 57 (1): 153–6. PMID 10036954.

[8] Soga, T; Matsuura, M; Kodama, Y; Fujita, T; Sekimoto, I; Nishimura, K; Yoshida, S; Kutsumi, H; Fujimoto, S (Avgust 1999). »Is a proton pump inhibitor necessary for the treatment of lower-grade reflux esophagitis?«. Journal of gastroenterology. 34 (4): 435–40. doi:10.1007/s005350050292. PMID 10452673.

[9] Borody, TJ; Andrews, P; Fracchia, G; Brandl, S; Shortis, NP; Bae, H (Oktober 1995). »Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori«. Gut. 37 (4): 477–81. doi:10.1136/gut.37.4.477. PMID 7489931.

[10] Hu, FL; Jia, JC; Li, YL; Yang, GB (2003). »Comparison of H2-receptor antagonist- and proton-pump inhibitor-based triple regimens for the eradication of Helicobacter pylori in Chinese patients with gastritis or peptic ulcer«. The Journal of international medical research. 31 (6): 469–74. doi:10.1177/147323000303100601. PMID 14708410.

[11] Kirika, NV; Bodrug, NI; Butorov, IV; Butorov, SI (2004). »[Efficacy of different schemes of anti-helicobacter therapy in duodenal ulcer]«. Terapevticheskii arkhiv. 76 (2): 18–22. PMID 15106408.

[12] Fujiwara, Y; Higuchi, K; Nebiki, H; Chono, S; Uno, H; Kitada, K; Satoh, H; Nakagawa, K; Kobayashi, K; Tominaga, K; Watanabe, T; Oshitani, N; Arakawa, T (Junij 2005). »Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease«. Alimentary pharmacology & therapeutics. 21 Suppl 2: 10–8. doi:10.1111/j.1365-2036.2005.02468.x. PMID 15943841.

[13] La Corte, R; Caselli, M; Castellino, G; Bajocchi, G; Trotta, F (Junij 1999). »Prophylaxis and treatment of NSAID-induced gastroduodenal disorders«. Drug safety. 20 (6): 527–43. doi:10.2165/00002018-199920060-00006. PMID 10392669.

[14] Laine, L; Kivitz, AJ; Bello, AE; Grahn, AY; Schiff, MH; Taha, AS (Marec 2012). »Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers«. The American journal of gastroenterology. 107 (3): 379–86. doi:10.1038/ajg.2011.443. PMID 22186979.

[15] Escolano, F; Castaño, J; López, R; Bisbe, E; Alcón, A (Oktober 1992). »Effects of omeprazole, ranitidine, famotidine and placebo on gastric secretion in patients undergoing elective surgery«. British journal of anaesthesia. 69 (4): 404–6. doi:10.1093/bja/69.4.404. PMID 1419452.

[16] Vila, P; Vallès, J; Canet, J; Melero, A; Vidal, F (november 1991). »Acid aspiration prophylaxis in morbidly obese patients: famotidine vs. ranitidine«. Anaesthesia. 46 (11): 967–9. doi:10.1111/j.1365-2044.1991.tb09860.x. PMID 1750602.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)

[17] Jahr, JS; Burckart, G; Smith, SS; Shapiro, J; Cook, DR (Julij 1991). »Effects of famotidine on gastric pH and residual volume in pediatric surgery«. Acta anaesthesiologica Scandinavica. 35 (5): 457–60. doi:10.1111/j.1399-6576.1991.tb03328.x. PMID 1887750.

[18] »Famotidine«.

[19] Fogg TB, Semple D (29. november 2007). »Combination therapy with H2 and H1 antihistamines in acute, non compromising allergic reactions«. BestBets. Manchester, England: Manchester Royal Infirmary. Pridobljeno 26. aprila 2011.

[20] »Pepcid Side Effects & Drug Interactions«. RxList.com. 2008. Pridobljeno 31. julija 2008.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]

[15]

[16]

[17]

[18]

[19]

[20]